Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies

References

• Sacar S, Hacioglu SK, Keskin A, Turgut H. Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey. J Infect Dev Ctries 2008;2:359–63.
   PubMedGoogle Scholar
• Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2010;138:1044–51.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with hematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721–8.
   PubMed Web of Science ®Google Scholar
• Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MÁ, Batlle M, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011;30:355–60.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66:657–63.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–10.
   PubMed Web of Science ®Google Scholar
• Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39:S25–S31.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 2013;98:1836–47.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.
   PubMed Web of Science ®Google Scholar
• Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490–4.
   PubMed Web of Science ®Google Scholar
• Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case–control study of predisposing factors. Clin Infect Dis 1992;14:1201–7.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al. Club de Réflexion sur les Infections en Onco-Hématologie. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149–58.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014;68:321–31.
   PubMed Web of Science ®Google Scholar
• Wojak I, Gospodarek E. Analysis of microorganisms isolated from febrile neutropenic children with neoplastic disease. Med Dosw Mikrobiol 2004;56:411–19.
   PubMedGoogle Scholar
• Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009;64:320–6.
   PubMed Web of Science ®Google Scholar
• Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A, et al. CIGAR (Gruppo Cooperativo Infezioni Gravi ed Antibiotico Resistenza). Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J Chemother 2006;18:589–602.
   PubMed Web of Science ®Google Scholar
• Rolston K. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients Int J Infect Dis 2006;10:223–30.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in a febrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005;19:CD004386.
   Google Scholar
• Safdar A, Rolston K. Stenotrophomonas maltophilia: changing spectrum of serious bacterial pathogens in patients with cancer. Clin Infect Dis 2007;45:1602–9.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–51.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013;19:474–9.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18. CLSI; 2008.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
   PubMed Web of Science ®Google Scholar
• Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955;11:375–86.
   Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009;58:299–307.
   PubMed Web of Science ®Google Scholar
• Gençer S, Batırel A, Özer S. The antibiotic susceptibilities of bacteria isolated from febrile neutropenic patients. Flora 2003;8:207–12.
   Google Scholar
• Akova M, Akan H. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Int J Antimicrob Agents 1999;13:15–19.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Dybdahl B, et al. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 2005;37:455–64.
   PubMed Web of Science ®Google Scholar
• Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al. Analysis of 4758 Escherichia coli bacteremia episodes: predictive factors for isolation of an antibiotic- resistant strain and their impact on outcome. J Antimicrob Chemother 2009;63:568–74.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al.;Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–87.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum betalactamase-producing enterobacteriaceae: an emerging public health concern. Lancet Infect Dis 2008;8:159–66.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum β-lactamase producing Escherichia coli. Arch Intern Med 2008;168:1897–902.
   PubMed Web of Science ®Google Scholar
• Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557–60.
   PubMed Web of Science ®Google Scholar
• Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009;53:1287–9.
   PubMed Web of Science ®Google Scholar
• Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;15:94–103.
   Google Scholar
• Zarakolu, P, Hasçelik G, Ünal S. Antimicrobial susceptibility pattern of nosocomial Gram negative pathogens: MYSTIC study results in Hacettepe University Adult Hospital (2000-2004). Mikrobiyol Bult 2006;40:147–54.
   PubMedGoogle Scholar
• McDonald P, Mitchell E, Johnson H, Rossney A, Humphreys H, Glynn G, et al. Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999. J Hosp Infect 2003; 54:130–4.
   PubMedGoogle Scholar
• MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, Gould IM. ARPAC Steering Group. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect 2007;13:269–76.
   PubMed Web of Science ®Google Scholar
• Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A. BSAC extended working party on bacteraemia resistance surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53:1018–32.
   PubMed Web of Science ®Google Scholar
• Elmaataoui A, Elghazouani M, Eric NA, Doghmi K, Mikdame M, Elhamzaoui S, et al. Blood isolates epidemiology in a clinical haematology department. Ann Biol Clin (Paris) 2009;67:293–7.
   PubMedGoogle Scholar
• Cattaneo C, Casari S, Bracchi F, Signorini L, Ravizzola G, Borlenghi E, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 2010;42:324–32.
   PubMed Web of Science ®Google Scholar